Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

unknown1
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

unknown133%
terminated133%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_3

Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes

NCT00433589
unknownphase_2

Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer

NCT00669370
terminatedphase_2

Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma

NCT00225056

Clinical Trials (3)

Showing 3 of 3 trials
NCT00433589Phase 3

Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes

Completed
NCT00669370Phase 2

Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer

Unknown
NCT00225056Phase 2

Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3